Skip to main content
Equibles
MLYS logo

MLYS · Mineralys Therapeutics, Inc. · Metrics

Track MLYS — free

Use MLYS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MLYS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$21.54 +0.07 (+0.33%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.90B
Shares
88.41M
Volume · Oct 22 824.73K Avg daily vol (3M) 1.13M

MLYS metrics

60 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$21.47
Market cap
$1.90B

Price action

20 metrics
Price change (1W)
-0.8%
Price change (30D)
-27.0%
Price change (3M)
-20.5%
Price change (6M)
-24.6%
Price change (YTD)
-40.8%
Price change (1Y)
-48.9%
Trailing year
Price change (5Y)
—
52-week high
$47.33
52-week low
$20.30
Change from 52-week high
-54.6%
Change from 52-week low
+5.8%
Annualized volatility
60.3%
Annualized volatility (3M)
56.6%
Beta
1.4
RSI (14D)
40.1
Price vs SMA 50
-15.7%
Price vs SMA 200
-21.6%
Avg volume (3M)
1.13M
Relative volume
0.7
Average dollar volume
$29.22M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
88.41M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.4
reciprocal yield 29.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-18.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-11

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$370.79M
Net income (TTM)
−$349.58M
Trailing 12 months
Diluted EPS (TTM)
$-4.16
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
$-3.06
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$7.93

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+29.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-63.5%
Return on assets
-52.3%
Debt / equity
0.0
Current ratio
34.5
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
34.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$138.17M
Latest balance sheet
Cash & equivalents
$138.27M
Total assets
$667.85M
Total debt
$100,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$138.79M
Capital expenditures (TTM)
$15,000
R&D (TTM)
$301.59M
SG&A (TTM)
—
Stock compensation (TTM)
$25.03M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
227
13F filer change QoQ
+9
Institutional ownership
115.8%
Conviction holders (share of 13F filers)
4.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+6.3%
Holder tenure
8.8
Price vs estimated holder cost
+13.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
12.6%

Short interest

3 metrics
Short interest
8.8%
Latest settlement · 5.2 days to cover
Days to cover
5.2d
Short-squeeze score
64 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$5.46M
Insider-sentiment score
27 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1933414 CUSIP 603170101 13F (30d) 17 filings 17 filers Visit website Investor relations